FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W26073183> ?p ?o ?g. }

• W26073183 endingPage "10" @default.
• W26073183 startingPage "S3" @default.
• W26073183 abstract "Recent trials have helped to clarify indications for the initial pharmacological therapy of hypertension. Both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) and World Health Organization-international Society of Hypertension (WHO-ISH) recommendations should be revised. The more recent trials indicate that: (1) diuretics and beta-blockers appear to be as effective in reducing overall morbidity/ mortality as other agents (Swedish Trial in Old Patients with Hypertension [STOP-2], United Kingdom Prospective Diabetes Study [UKPDS], Intervention as a Goal in Hypertension Treatment [INSIGHT], Nordic diltiazem [NORDIL]); (2) the use of an a-blocker results in more cardiovascular events, especially congestive heart failure, when compared with a diuretic (Antihypertensive Therapy and Lipid Lowering Heart Attack Trial [ALLHAT]); (3)the use of an angiotensin-converting enzyme (ACE) inhibitor results in fewer myocardial infarctions and episodes of heart failure than calcium channel blockers in the elderly and in diabetic patients (Fosinopril vs. Amlodipine Cardiovascular Events Randomized Trial [FACET], Appropriate Blood Pressure Control in Diabetes [ABCD], STOP-2) - other data (Captopril Prevention Project [CAPPP]) suggest that the use of an ACE inhibitor is preferred in diabetic patients; (4) overall cardiovascular events are similar with calcium channel blockers compared with a diuretic - however, there are fewer strokes with non-dihydropyridine calcium channel blockers (NORDIL) and a trend towards an increase in heart failure and myocardial infarctions with either a dihydropyridine or non-dihydropyridine calcium channel blockers compared with a diuretic (INSIGHT, NORDIL); (5) angiotensin receptor blockers (ARBs) will decrease proteinuria and slow progression of renal disease in type 2 diabetic patients when compared with regimens that do not include an ARB or an ACE inhibitor (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan [RENAAL], Irbesartan Type II Diabetic Nephropathy Trial [IDNT], Irbesartan Type II Diabetes with Microalbuminuria [IRMA Il]). The debate over initial therapy may be moot. High-risk hypertensive patients should probably be treated initially with combination therapy, one of which should be a diuretic. The use of diuretics and beta-blockers as well as ACE-inhibitors alone or with a diuretic should be considered as initial therapy (a change from JNCVI). Alpha-blockers should be reserved for special situations, i.e. prostatic hypertrophy (in contrast to WHO-ISH recommendations). An ACE-inhibitor or ARB, usually along with a diuretic, can be considered as preferred therapy in hypertensive diabetic patients. Some data suggest equal or greater reduction in strokes with a calcium channel blocker than other medications." @default.
• W26073183 created "2016-06-24" @default.
• W26073183 creator A5056054137 @default.
• W26073183 date "2002-02-01" @default.
• W26073183 modified "2023-09-29" @default.
• W26073183 title "Current recommendations for the treatment of hypertension: are they still valid?" @default.
• W26073183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11996197" @default.
• W26073183 hasPublicationYear "2002" @default.
• W26073183 type Work @default.
• W26073183 sameAs 26073183 @default.
• W26073183 citedByCount "9" @default.
• W26073183 countsByYear W260731832016 @default.
• W26073183 countsByYear W260731832020 @default.
• W26073183 crossrefType "journal-article" @default.
• W26073183 hasAuthorship W26073183A5056054137 @default.
• W26073183 hasConcept C126322002 @default.
• W26073183 hasConcept C134018914 @default.
• W26073183 hasConcept C164705383 @default.
• W26073183 hasConcept C27016395 @default.
• W26073183 hasConcept C2776741139 @default.
• W26073183 hasConcept C2778198053 @default.
• W26073183 hasConcept C2779479957 @default.
• W26073183 hasConcept C2779611605 @default.
• W26073183 hasConcept C2779646130 @default.
• W26073183 hasConcept C2779918671 @default.
• W26073183 hasConcept C2780356492 @default.
• W26073183 hasConcept C2780436477 @default.
• W26073183 hasConcept C2781212610 @default.
• W26073183 hasConcept C519063684 @default.
• W26073183 hasConcept C555293320 @default.
• W26073183 hasConcept C71924100 @default.
• W26073183 hasConcept C84393581 @default.
• W26073183 hasConcept C85520022 @default.
• W26073183 hasConceptScore W26073183C126322002 @default.
• W26073183 hasConceptScore W26073183C134018914 @default.
• W26073183 hasConceptScore W26073183C164705383 @default.
• W26073183 hasConceptScore W26073183C27016395 @default.
• W26073183 hasConceptScore W26073183C2776741139 @default.
• W26073183 hasConceptScore W26073183C2778198053 @default.
• W26073183 hasConceptScore W26073183C2779479957 @default.
• W26073183 hasConceptScore W26073183C2779611605 @default.
• W26073183 hasConceptScore W26073183C2779646130 @default.
• W26073183 hasConceptScore W26073183C2779918671 @default.
• W26073183 hasConceptScore W26073183C2780356492 @default.
• W26073183 hasConceptScore W26073183C2780436477 @default.
• W26073183 hasConceptScore W26073183C2781212610 @default.
• W26073183 hasConceptScore W26073183C519063684 @default.
• W26073183 hasConceptScore W26073183C555293320 @default.
• W26073183 hasConceptScore W26073183C71924100 @default.
• W26073183 hasConceptScore W26073183C84393581 @default.
• W26073183 hasConceptScore W26073183C85520022 @default.
• W26073183 hasIssue "1" @default.
• W26073183 hasLocation W260731831 @default.
• W26073183 hasOpenAccess W26073183 @default.
• W26073183 hasPrimaryLocation W260731831 @default.
• W26073183 hasRelatedWork W2013940678 @default.
• W26073183 hasRelatedWork W2038608656 @default.
• W26073183 hasRelatedWork W2041391541 @default.
• W26073183 hasRelatedWork W2260451204 @default.
• W26073183 hasRelatedWork W2282016799 @default.
• W26073183 hasRelatedWork W2413265658 @default.
• W26073183 hasRelatedWork W2443217093 @default.
• W26073183 hasRelatedWork W26073183 @default.
• W26073183 hasRelatedWork W2904986847 @default.
• W26073183 hasRelatedWork W2188782894 @default.
• W26073183 hasVolume "20" @default.
• W26073183 isParatext "false" @default.
• W26073183 isRetracted "false" @default.
• W26073183 magId "26073183" @default.
• W26073183 workType "article" @default.